三生制药今日盘中股价出现大跌，跌幅达7.40%，引发市场关注。
消息面上，此次下跌主要与生物科技板块整体回调有关。此前，在美国临床肿瘤学会（ASCO）年会期间，三生制药的核心管线SSGJ-707公布了亮眼的II期临床数据，推动其股价在近期连续大涨。随着ASCO相关利好的集中释放，整个生物科技板块在今日出现获利回吐压力，科伦博泰生物、康方生物、荣昌生物等多只个股均显著下跌，三生制药亦随之承压。
此次板块性的回调，反映了市场在短期利好兑现后的正常调整行为。三生制药在经历前期上涨后，股价随板块波动属于市场常见现象。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.